With the obesity epidemic contributing to rising rates of diabetes, heart disease and other chronic conditions, GLP-1 therapies represent a potential turning point in the fight against these diseases
Read the full study: Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes (Lancet 2023)
The solution was centrifuged at 1,000 g for 5 min, and the absorbance of the supernatant was measured at 280 nm to determine the lignin content
Here is what that means for you
Jordy AB, Albayaty M, Breitschaft A, et al
But in a world where information comes hard and fast it is very difficult to decipher what works and what doesn't, what to take, and what not to, when it comes to your health